ObsEva SA (OBSV)
(Delayed Data from NSDQ)
$13.89 USD
-0.12 (-0.86%)
Updated May 3, 2019 04:13 PM ET
After-Market: $13.76 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[OBSV]
Reports for Purchase
Showing records 21 - 40 ( 170 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Ebopiprant Partnership Validates Development Strategy; Focus Now on Linzagolix
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Validating Ebopiprant License Agreement Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Yselty''s Pilot Study Data in Adenomyosis at ESHRE; Ebopiprant P2 at SRI
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Ebopiprant PROLONG Phase 2 Trial Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
YSELTY?/UF: 76-Week PRIMROSE 1 Data Shows Sustained Benefit; NDA in Q3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Q1 Financials; Key 2021 Catalysts and Pipeline Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Linzagolix EDELWEISS 3 Pivotal Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
PRIMROSE 3 Linzagolix Long-Term Safety Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
YSELTY?/UF: Initiated Long-Term PRIMROSE 3 Study to Assess Bone Mineral Density
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Balance Sheet Strengthened; 2020 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Q4/FY20 Financials; Next, YSELTY?/UF NDA Submission Anticipated in Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Several Key Clinical & Regulatory Catalysts Anticipated in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
YSELTY European Application Accepted; U.S. Trial Discontinued; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
YSELTY?/UF: MAA Validated; PRIMROSE-1 76-Week Data in Q1 & NDA Submission in H1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Linzagolix Competitive Landscape More Challenging; Reducing PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
New Linzagolix/UF Phase 3 Data Demonstrates Sustained Clinical Benefit
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Linzagolix/UF: MAA Submitted; Next: 52-Week PRIMROSE-1 Data in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Positive Clinical Proof-of-Concept Results for Ebopiprant/ Preterm Labor
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L